ArticleJournal of translational medicine2026

FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target.

Valentina Doldi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.